CXCR4 and thyroid cancer: For example, the efficacy of sorafenib, the first multi-kinase inhibitor (including VEGFRs) approved to treat RAIR differentiated thyroid cancer, has been shown to be closely correlated with a tip EC marker CXCR4 in hepatocellular carcinoma58.